Navigation Links
ApexPro FH

ProductsApexPro FH
Company GE Healthcare
Item ApexPro FH
Features 
  • Bi-directional communication and frequency-hopping spread spectrum technologies
  • Built on the EK-Pro clinical foundation, ApexPro FH delivers patient safety through dual V-leads, atrial fibrillation detection, and four-lead simultaneous arrhythmia analysis
  • Patient monitoring has more than 640 channels in WMTS
  • Industry-standard IT infrastructure and bi-directional capability position ApexPro FH to deliver many more innovative clinical and workflow features as they become available
Description The ApexPro FH system uses a frequency-hopping spread spectrum wireless infrastructure operating in the WMTS for dependable communication of patient information. ApexPro FH offers scalability of up to 640 channels in WMTS and bi-directional communication.
Info GE HealthcareCall GE Healthcare to buy products (US and Canada only; other locations use number below) USACanada1-866-903-4021

Customer Service: 1-800-957-6837
Web site: http://www.gehealthcare.com/

Related medicine products :

1. ApexPro CH
TAG: ApexPro
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products:
(Date:9/5/2008)...scuss the Latest Developments in Molecular,Testing...t. 5 /PRNewswire-USNewswire/ -- The practice of,pa...sting and the promise,of personalized medicine wil...des and other imaging technologies will change the...thologists is taking a leadership role in,making s...
(Date:9/5/2008)...5 /PRNewswire-USNewswire/ -- The Health Resources,... $39 million in grants to,increase and improve med...hese grants continue President Bush,s historic exp...s now reach more economically,vulnerable and geogr...SA,Administrator Elizabeth M. Duke said. "In 2007,...
(Date:9/5/2008)...eoretical ,anti-cloak, could bring objects out of ...ws) -- Just in case someone develops a cloak of in...know how to uncloak the objects it hides. , Acc...ertain materials underneath an invisibility cloak ..., Researchers at Shanghai Jiao Tong University in...
(Date:9/5/2008)... McCain to commit to develop a National AIDS,Strat..., Sep. 5 /PRNewswire-USNewswire/ -- The,Republican...mention of the,domestic AIDS epidemic in the Unite...c overseas. Neither Presidential nominee Sen. John...alin mentioned AIDS in their remarks,to Convention...
Breaking Medicine News(10 mins):Health News:Leaders in Pathology Meet in San Diego: Sept. 25 - 28, 2008 2Health News:HRSA Announces $39 Million in Grants to Expand, Improve Health Center Services 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 2Health News:Domestic AIDS Epidemic Ignored at Republican National Convention 3
...time, researchers have shown that plant growth is ...ight . Using time-lapse photography, post-doctora...the University of California, Davis, and the Unive...d that the shoots of Arabidopsis seedlings show a ...
...or claimed Tuesday a world first after restoring t...rapy and other cancer treatment. The gynaecologi...ed ovarian tissue from the woman's sister last yea...ersitaires Saint-Luc in Brussels. "To this day, m...
...scribed as the stone that kills two vices. United ...enicline , is posing to be handed out to alcoholic...nder the name Chantix, which has been used quite s... was tested to reveal the same effects in alcoholi...
...sentations at the ESMO Conference Lugano this week...evels of prostate specific antigen, a marker of c...hom hormone therapy had stopped working and also i...ted with chemotherapy. For prostate cancer patien...
Other Medicine News:Health News:Two In One Drug For Smokers And Drinkers 2Health News:Hormone Inhibitor in Prostate Cancer Treatment 2
(Date:9/4/2008)...ember 4 /- Axentis Pharma AG has,init...ety and tolerability,of a new therapeutic formulat...n in cystic fibrosis patients. The new formulation...ivered directly to the site of,infection. The fort...,different doses of the new drug. Initial results ...
(Date:9/3/2008)...4 /Xinhua--,Pharmaceutical ...nnounced,that it has enrolled the first subject in...ating Bronchitol in cystic fibrosis sufferers., T...s across North,America, Argentina and Germany, and... approval to market Bronchitol for cystic fibrosis...
(Date:9/3/2008)...nal Vascular Disease Awareness Month, CHARLOTTESV...aceuticals,LLC, a clinical-stage drug-development ...t of unmet medical needs, announced today that it ...cal trial of its lead drug,candidate trans sodium ...81,on the clinicaltrials.gov Website, is investiga...
(Date:9/3/2008)...s, Updates Zingo Launch Progress and Adlea ... Conference Call Today at 11:30 am ET, SOUTH...all/ -- Anesiva,Inc. (Nasdaq: ANSV ) announced t...to focus on commercial and late-stage product deve...y pharmaceutical pain management,company. The comp...
Breaking Medicine Technology:Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 2Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 3Cystic Fibrosis Axentis Pharma Initiates Clinical Trial for Lung Infections 4Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 2Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 2Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 3Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD) 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 2Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 3Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 4Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company 5UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed 14565 1UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed 14565 2UFE Highly Effective in Cases Where Focused Ultrasound to Treat Uterine Fibroids Failed 14565 3New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow Stem Cell Transplants 14561 1New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow Stem Cell Transplants 14561 2New Interventional Radiology Treatment Shows Hope for People With Complications from Bone Marrow Stem Cell Transplants 14561 3Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 14557 1Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 14557 2Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 14557 3Few Women Hear About Uterine Fibroid Embolization Treatment Option Directly From Gynecologists 14557 4Competitive Intelligence 3A Information Collection Tactics 14554 1
...TH, N.J., May 18, 2007 /PRNewswire-FirstCall/ -- A...ical studies with,Schering-Plough,s hepatitis prod...2b) and REBETOL(R) (ribavirin, USP) combination,th...n, as well as,boceprevir (SCH 503034), the company...rently in Phase II clinical development, will,be p...
...ut of 10 non-diabetic patients treated with,Exforg...Additional average decrease of 20 mmHg in,systolic...e over,reductions seen with previous monotherapy[1...not,at treatment target levels[2] and most require... , BASEL, Switzerland, May 21, 2007 - Exforge®...
Other Medicine Technology:Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 2Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 3Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 4Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 5Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 6Schering-Plough Announces Hepatitis C Data Presentations at,Digestive Disease Week (DDW) 2007 Annual Meeting 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8